Hikma Pharmaceuticals Plc Circ re. Roxane Acquisition and EGM (7594M)
January 22 2016 - 9:04AM
UK Regulatory
TIDMHIK
RNS Number : 7594M
Hikma Pharmaceuticals Plc
22 January 2016
Publication of combined prospectus and circular
London, 22 January 2016 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ("Hikma"), the fast growing pharmaceuticals company,
announced on 28 July 2015 that it had agreed terms to acquire
Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from
Boehringer Ingelheim (the "Acquisition"). A combined prospectus and
circular which contains further details of the Acquisition (the
"Prospectus") has been published and will be posted to
shareholders.
The Prospectus has been prepared by Hikma in relation to the
admission to the premium listing segment of the Official List and
to trading on the London Stock Exchange of 40,000,000 Consideration
Shares of 10 pence each in Hikma and for the purposes of, among
other things, seeking shareholder approval for the Acquisition. The
Consideration Shares will be issued and allotted to Boehringer
Ingelheim on completion of the Acquisition. The Prospectus contains
the formal notice of meeting for the general meeting, to be held on
19 February 2016.
As required by Listing Rules 9.6.1R and 9.6.3R and Prospectus
Rule 3.2.1R, a copy of the Prospectus has been approved by the
Financial Conduct Authority and published and submitted to the
National Storage Mechanism and will shortly be available for
inspection at www.morningstar.co.uk/uk/NSM.
Posting of the Prospectus is expected to be completed on 25
January 2016.
Capitalised terms used in this announcement have the meanings
given to them in the Prospectus. The Prospectus is available on the
Company's website
(www.hikma.com/en/investors/shareholder-services/circular-and-egm.aspx)
and may be inspected at the registered office of the Company at 13
Hanover Square, London W1S 1HL.
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary
+44 (0)20 7399 2772
Susan Ringdal, Vice President, Corporate Strategy
& Investor Relations +44 (0)20 7399 2760
Financial Dynamics
Matthew Cole & Ben Atwell +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million.
Disclaimer
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE A PROSPECTUS OR EQUIVALENT. INVESTORS SHOULD NOT
SUBSCRIBE FOR OR PURCHASE ANY SECURITIES REFERRED TO IN THIS
ANNOUNCEMENT. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN INVITATION
OR OFFER TO SELL OR EXCHANGE OR THE SOLICITATION OF AN INVITATION
OR OFFER TO BUY OR EXCHANGE ANY SECURITIES IN THE UNITED STATES OR
ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO PRIOR TO
REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF SUCH
JURISDICTION. NONE OF THE SECURITIES REFERRED TO IN THIS
ANNOUNCEMENT SHALL BE SOLD, ISSUED, EXCHANGED OR TRANSFERRED IN ANY
JURISDICTION IN CONTRAVENTION OF APPLICABLE LAW. THE SECURITIES
HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES
ACT, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR
OTHER JURISDICTION AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON
AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE
STATE OR LOCAL SECURITIES LAWS. THERE WILL BE NO PUBLIC OFFERING OF
SECURITIES IN THE UNITED STATES.
CITIGROUP GLOBAL MARKETS LIMITED ("CITI"), WHICH IS AUTHORISED
BY THE PRUDENTIAL REGULATION AUTHORITY AND REGULATED BY THE
FINANCIAL CONDUCT AUTHORITY AND THE PRUDENTIAL REGULATION
AUTHORITY, IS ACTING EXCLUSIVELY FOR HIKMA AND NO ONE ELSE IN
CONNECTION WITH THE ACQUISITION AND WILL NOT BE RESPONSIBLE TO
ANYONE OTHER THAN HIKMA FOR PROVIDING THE PROTECTIONS AFFORDED TO
CLIENTS OF CITI OR FOR PROVIDING ADVICE IN RELATION TO THE
ACQUISITION OR ANY OTHER MATTERS REFERRED TO IN THIS ANNOUNCEMENT.
NEITHER CITI NOR ANY OF ITS DIRECTORS, OFFICERS, REPRESENTATIVES,
EMPLOYEES, ADVISERS, AGENTS OR AFFILIATES OWES OR ACCEPTS ANY DUTY,
LIABILITY OR RESPONSIBILITY WHATSOEVER (WHETHER IN CONTRACT, IN
TORT, UNDER STATUTE OR OTHERWISE) TO ANY PERSON WHO IS NOT A CLIENT
OF CITI IN CONNECTION WITH THIS ANNOUNCEMENT, ANY STATEMENT
CONTAINED HEREIN, THE ACQUISITION OR OTHERWISE.
-- ENDS --
This information is provided by RNS
The company news service from the London Stock Exchange
END
CIRXLLFLQFFEBBK
(END) Dow Jones Newswires
January 22, 2016 09:04 ET (14:04 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024